Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,700 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 6 April 2021) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at so that we can update the bibliography.


 (PDF, 5MB, 226 pages) 

This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website



Export 70 results:
Author [ Title(Asc)] Type Year
Filters: Author is Leufkens, H. G.  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
T. P. van Staa, Leufkens, H. G., Zhang, B., and Smeeth, L., A comparison of cost effectiveness using data from randomized trials or actual clinical practice: selective cox-2 inhibitors as an example, PLoS Med, vol. 6, p. e1000194, 2009.
H. A. van den Ham, Klungel, O. H., Singer, D. E., Leufkens, H. G., and van Staa, T. P., Comparative Performance of ATRIA, CHADS2, and CHA2DS2-VASc Risk Scores Predicting Stroke in Patients With Atrial Fibrillation: Results From a National Primary Care Database, J Am Coll Cardiol, vol. 66, pp. 1851-9, 2015.
T. P. van Staa, Geusens, P., Bijlsma, J. W., Leufkens, H. G., and Cooper, C., Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis, Arthritis Rheum, vol. 54, pp. 3104-12, 2006.
T. P. van Staa, Cooper, C., Leufkens, H. G., and Bishop, N., Children and the risk of fractures caused by oral corticosteroids, J Bone Miner Res, vol. 18, pp. 913-8, 2003.
E. Setakis, Leufkens, H. G., and van Staa, T. P., Changes in the characteristics of patients prescribed selective cyclooxygenase 2 inhibitors after the 2004 withdrawal of rofecoxib, Arthritis Rheum, vol. 59, pp. 1105-11, 2008.
A. Lalmohamed, Bazelier, M. T., van Staa, T. P., Uitdehaag, B. M., Leufkens, H. G., de Boer, A., and de Vries, F., Causes of death in patients with multiple sclerosis and matched referent subjects: a population-based cohort study, Eur J Neurol, vol. 19, pp. 1007-14, 2012.
T. P. van Staa, Bishop, N., Leufkens, H. G., and Cooper, C., Are inhaled corticosteroids associated with an increased risk of fracture in children?, Osteoporos Int, vol. 15, pp. 785-91, 2004.
C. Klop, Gibson-Smith, D., Elders, P. J., Welsing, P. M., Leufkens, H. G., Harvey, N. C., Bijlsma, J. W., van Staa, T. P., and de Vries, F., Anti-osteoporosis drug prescribing after hip fracture in the UK: 2000-2010, Osteoporos Int, vol. 26, pp. 1919-28, 2015.
V. Abbing-Karahagopian, Huerta, C., Souverein, P. C., de Abajo, F., Leufkens, H. G., Slattery, J., Alvarez, Y., Miret, M., Gil, M., Oliva, B., Hesse, U., Requena, G., de Vries, F., Rottenkolber, M., Schmiedl, S., Reynolds, R., Schlienger, R. G., de Groot, M. C., Klungel, O. H., van Staa, T. P., van Dijk, L., Egberts, A. C., Gardarsdottir, H., and De Bruin, M. L., Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implications, Eur J Clin Pharmacol, vol. 70, pp. 849-57, 2014.
E. M. van de Garde, Souverein, P. C., Hak, E., Deneer, V. H., van den Bosch, J. M., and Leufkens, H. G., Angiotensin-converting enzyme inhibitor use and protection against pneumonia in patients with diabetes, J Hypertens, vol. 25, pp. 235-9, 2007.
[Page last reviewed 6 April 2021]